$NEO News
Last published 2w ago
- 2w agoNEONeoGenomics Third Quarter 2026 Earnings Call - NEOGENOMICS INCEarnings Call TranscriptsGood afternoon, and welcome to the Neogenomics Third Quarter 2026 Financial Results Conference Call. Please be advised that today's conference is being recorded. I will now turn the call over to Andrew Brackman, Vice Pre
- 2w agoNEONEOGENOMICS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoNEONeoGenomics Reports Third Quarter 2026 ResultsBusiness WireTotal revenue increased 11% YoY to $209 million Clinical services revenue grew 13%, with NGS revenue growth of 29% Company raises full-year 2026 revenue and adjusted EBITDA guidance NeoGenomics, Inc. (NASDAQ:NEO)
- 3w agoNEONeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital PathologyBusiness WireThe collaboration is designed to support faster, more informed care for patients and providers NeoGenomics, Inc. (NASDAQ:NEO), a provider of oncology diagnostic solutions that enable precision medicine across the
- 4w agoNEONeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026Business WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2026 financial results after the close of the
- 1mo agoNEONeoGenomics Announces Executive Leadership and Board of Directors Succession PlanBusiness WireWarren Stone, current President and COO, to become CEO and a member of the Board effective January 4, 2027Tony Zook to remain CEO through January 3, 2027, and become Executive Chairman effective January 4, 2027Lynn
- 1mo agoNEONeoGenomics Laboratories, Inc. - 1773793 - NEOGENOMICS INCEarnings Call TranscriptsThank you everyone for joining us. It's my pleasure to introduce the Neogenomics team. We're glad to have you here at the Morgan Stanley Healthcare Conference this morning. I'm joined by Tony Zook, Chief Executive Office
- 1mo agoNEONeoGenomics Laboratories, Inc. - 1773793 - NEOGENOMICS INCEarnings Call TranscriptsThank you everyone for joining us. It's my pleasure to introduce the Neogenomics team. We're glad to have you here at the Morgan Stanley Healthcare Conference this morning. I'm joined by Tony Zook, Chief Executive Office
- 2mo agoNEONeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that the Company will participate in the Morgan Stanley 24th Annual Global Healthcare
- 2mo agoNEONeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response MonitoringBusiness WireNew coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic
- 3mo agoNEONeoGenomics Second Quarter 2026 Earnings Call - NEOGENOMICS INCEarnings Call TranscriptsGood afternoon, and welcome to the Neogenomics Second Quarter 2026 Financial Results Call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. I will now
- 3mo agoNEONeoGenomics Reports Second Quarter 2026 ResultsBusiness WireTotal revenue increased 11% YoY to $202 million Clinical services revenue grew 14%, with NGS revenue growth of 26% Company raises full-year 2026 revenue and adjusted EBITDA guidance NeoGenomics, Inc. (NASDAQ:NEO)
- 3mo agoNEONeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHSBusiness WireNeoGenomics, Inc. (the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department
- 4mo agoNEONeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate CancerBusiness WireAvailable within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP® NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology
- 4mo agoNEONeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026Business WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S.
- 4mo agoNEONeoGenomics Appoints Carolyn Starrett to its Board of DirectorsBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors. Ms. Starrett brings
- 4mo agoNEONeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior NotesBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million aggregate
- 5mo agoNEONeoGenomics to Present New Research at ASCO Annual Meeting 2026Business WirePresentations highlight advances in MRD, precision oncology, and real-world evidence across solid tumors and hematologic malignancies NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions
- 6mo agoNEONeoGenomics to Participate in Upcoming Investor ConferencesBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual
- 6mo agoNEONeoGenomics First Quarter 2026 Earnings Call - NeoGenomicsEarnings Call TranscriptsGood afternoon, and welcome to the Neogenomics First Quarter 2026 Financial Results Call. Please be advised that today's conference is being recorded. I will now turn the call over to Priya Vidharaman, Senior Vice Presid
- 6mo agoNEONeoGenomics Reports First Quarter 2026 ResultsBusiness WireFirst quarter total revenue increased 11% YoY to $187 million; Clinical revenue grew 14%, including NGS growth of 26%; Company announces increase in full-year 2026 revenue guidance to a range of $797-$803
- 6mo agoNEONeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura IntegrationBusiness WireEHR-enabled access has the potential to streamline ordering, accelerate clinical decisions, and drive scalable precision oncology adoption NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic
- 7mo agoNEONeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026Business WireThe Company will highlight integrated clinical and genomic insights generated through its Oncology Data Solutions platform NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that
- 7mo agoNEONeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026Business WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the
- 8mo agoNEONeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy ProfilingBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the PanTracer™ LBx test has received coverage from the Centers for Medicare
- 8mo agoNEONeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor TypesBusiness WireWe estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic
- 8mo agoNEONeoGenomics to Participate in Upcoming Investor ConferencesBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: TD Cowen 46th
- 8mo agoNEONeoGenomics Reports Fourth Quarter and Full Year 2025 ResultsBusiness WireFull-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent litigation NeoGenomics, Inc. (NASDAQ:NEO) (the
- 9mo agoNEONeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy SelectionBusiness WireNew integrated testing approach provides potential to deliver earlier biomarker insights, reduce diagnostic uncertainty in complex cancer cases, and enable confident clinical decisions NeoGenomics, Inc. (NASDAQ:NEO),
- 9mo agoNEONeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026Business WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to
- 10mo agoNEONeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 RevenueBusiness Wire– Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc.
- 10mo agoNEONeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the upcoming 44th Annual J.P. Morgan Healthcare
- 10mo agoNEONeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of DirectorsBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny
- 11mo agoNEONeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent LitigationBusiness WireNeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable
- 11mo agoNEONeoGenomics to Present New ctDNA Research at SABCS 2025Business WireData include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic
- 11mo agoNEONeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025Business WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and
- 1y agoNEONeoGenomics to Participate in Upcoming Investor ConferencesBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: Stephens Annual
- 1y agoNEONeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid TumorsBusiness WireAdditional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across solid tumors NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable
- 1y agoNEONeoGenomics Reports Third Quarter 2025 ResultsBusiness WireThird quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24% YoY and now accounts for nearly one-third of clinical
- 1y agoNEONeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025Business WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the presentation of assay-relevant data, including interventional therapy trials in
- 1y agoNEONeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025Business WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2025 financial results prior to the open of the
- 1y agoONCYNEOGHCLRB+1Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market ExpandsPR NewswireCancer innovation is reaching new heights as the FDA approved breakthrough therapies for aggressive malignancies, including Modeyso for deadly brain...
- 1y agoNEOCourt Rules for NeoGenomics in Patent Infringement Lawsuit Against NateraBusiness Wire– NeoGenomics wins summary judgment in patent infringement lawsuit against Natera; Court rules Natera's patents are invalid for claiming ineligible subject matter – NeoGenomics remains free to make, use, sell, and
- 1y agoNEONeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid BiopsyBusiness WireNew ctDNA-based test offers a flexible, guideline-driven solution for patients with advanced solid tumors when tissue is limited or unavailable NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic
- 1y agoNEONeoGenomics, Inc. (NEO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoNEONeoGenomics Reports Second Quarter 2025 ResultsBusiness WireSecond Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology
- 1y agoNEONeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025Business WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the
- 1y agoNEONeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer CareBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay,
- 1y agoNEONeoGenomics Appoints Dr. Marjorie Green to Board of DirectorsBusiness WireNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.
- 1y agoNEONeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025Business WireThe company expands precision oncology portfolio with new Paletrra spatial proteomics platform NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that